博乐欣缓释片与氯丙咪嗪治疗抑郁症的疗效及安全性分析(1)
 |
| 第1页 |
参见附件(2027KB，2页)。
[摘要] 目的 比较观察博乐欣缓释片与氯丙咪嗪治疗抑郁症的疗效及安全性。方法 2010年1月～2011年1月92例抑郁症患者随机分为博乐欣组和氯丙咪嗪组，每组46例，对比观察两组的临床疗效、HAMD评分及不良反应。结果 博乐欣组与氯丙咪嗪的总有效率比较，P>0.05。博乐欣组治疗后1、2和4周HAMD评分明显低于治疗前水平，差异有统计学意义(P<0.05)；而氯丙咪嗪组仅治疗后2和4周HAMD评分明显低于治疗前水平(P<0.05)。博乐欣组治疗后1周HAMD评分低于同期氯丙咪嗪组，差异有统计学意义(P<0.05)。博乐欣组不良反应发生率明显低于氯丙咪嗪组，两组间的差异具有统计学意义(P<0.05)。结论 博乐欣与氯丙咪嗪治疗抑郁症的疗效相当，但博乐欣起效更快，并且不良反应少，可在临床推广应用。
[关键词] 博乐欣缓释片；氯丙咪嗪；疗效；安全性
[中图分类号] R749.4[文献标识码] B[文章编号] 1673-9701(2011)27-55-02
Efficacy and Safety of Venlafaxine Hydrochloride Sustained-release Tablets and Clomipramine in Treatment of Episode Depression
CHEN Lianzhou
Ningbo Mental Hospital, Ningbo 315000, China
[Abstract] Objective To compare the effect and safety of venlafaxine hydrochloride sustained-release tablets and clomipramine in treatment of episode depression. Methods 92 cases episode depression patients were divided into two groups from January 2010 to January 2011, which venlafaxine hydrochloride group with 46 cases and clomipramine group with 46 cases. The clinical efficacy, HAMD scores and adverse effect of the two groups were compared. Results There was no significant difference in clinical efficacy between the two groups(P>0.05). Compared with pre-treatment, the scores of HAMD scores were significantly decreased in venlafaxine hydrochloride group after treatment 1 week, 2 weeks and 4 weeks(P<0.05)and in clomipramine group after treatment 2 weeks and 4 weeks(P<0.05). After treatment for 1 week, the HAMD score of venlafaxine hydrochloride group was significantly lower than that of clomipramine group(P<0.05). The adverse reaction rate of venlafaxine hydrochloride group was significantly lower than that of clomipramine group(P<0.05). Conclusion The venlafaxine hydrochloride sustained-release tablet is equal to clomipramine in clinical effect but can be effective quickly, which can be applied in clinic.
[Key words] Venlafaxine hydrochloride sustained-release tablet；Clomipramine；Efficacy；Safety
随着人们的生活节奏的加快，社会压力也越来越大，容易产生抑郁等消极情绪，导致抑郁症的发病率不断升高[1] ......
您现在查看是摘要介绍页，详见PDF附件(2027KB，2页)。